Legend Biotech Corp. (LEGN) is a clinical-stage biotechnology company that develops and commercializes cell therapy products for the treatment of cancer and other serious diseases. The company's lead product candidate is LCAR-B38M/JNJ-4528, an investigational chimeric antigen receptor (CAR) T-cell therapy for the treatment of multiple myeloma. Legend Biotech is also developing other CAR T-cell therapies for the treatment of solid tumors and hematological malignancies. The company's proprietary technology platform, CAR-T 2.0, is designed to enhance the efficacy and safety of CAR T-cell therapies. Legend Biotech is headquartered in Somerset, New Jersey, and as of September 2021, had a market capitalization of approximately $4.24 billion. The company is a subsidiary of GenScript Biotech Corporation, a global biotechnology company based in China.
Legend Biotech Corp. (LEGN) is a clinical-stage biotechnology company that develops and commercializes cell therapy products for the treatment of cancer and other serious diseases. The company's lead product candidate is LCAR-B38M/JNJ-4528, an investigational chimeric antigen receptor (CAR) T-cell therapy for the treatment of multiple myeloma. Legend Biotech is also developing other CAR T-cell therapies for the treatment of solid tumors and hematological malignancies. The company's proprietary technology platform, CAR-T 2.0, is designed to enhance the efficacy and safety of CAR T-cell therapies. Legend Biotech is headquartered in Somerset, New Jersey, and as of September 2021, had a market capitalization of approximately $4.24 billion. The company is a subsidiary of GenScript Biotech Corporation, a global biotechnology company based in China.